IL-7 Inhibitors
IL-7, or interleukin-7, plays a crucial role in regulating immune responses, particularly in the development, survival, and homeostasis of T cells. While there may not be specific chemicals identified as direct inhibitors of IL-7, various compounds indirectly modulate IL-7 signaling by targeting key components of the pathways involved in IL-7-mediated effects. Tofacitinib, Ruxolitinib, and Baricitinib are Janus kinase (JAK) inhibitors that indirectly influence IL-7 signaling by disrupting the JAK-STAT pathway activated by IL-7. These compounds interfere with downstream cellular responses, impacting T cell development and survival, among other IL-7-dependent processes. TAK-242, a Toll-like receptor 4 (TLR4) inhibitor, indirectly influences IL-7 signaling by modulating immune responses. Through the inhibition of TLR4-mediated pathways, TAK-242 may alter the inflammatory milieu, potentially impacting IL-7-related processes in immune cells.
Wortmannin and LY294002, phosphoinositide 3-kinase (PI3K) inhibitors, can indirectly modulate IL-7 signaling by interfering with downstream pathways involved in cell survival and growth. These compounds may affect IL-7-dependent processes, including the survival and proliferation of T cells and other IL-7-responsive cells. TG101348, a JAK2 inhibitor, and BMS-986165, a TYK2 inhibitor, indirectly influence IL-7 signaling by targeting JAKs and TYK2, respectively, disrupting the JAK-STAT pathway activated by IL-7. TWS119, a glycogen synthase kinase 3 (GSK-3) inhibitor, indirectly influences IL-7 signaling by modulating downstream pathways involved in cell survival and proliferation. This indirect modulation may impact IL-7-dependent processes in T cells and other IL-7-responsive cells. In summary, while direct IL-7 inhibitors might be limited, a diverse array of chemicals can indirectly modulate IL-7 signaling by targeting key components of the pathways involved. These compounds offer valuable insights into the complex regulatory networks that govern IL-7-mediated effects on immune cell function and homeostasis.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib, a JAK1 and JAK2 inhibitor, similarly affects IL-7 signaling through the JAK-STAT pathway. By inhibiting JAKs, Ruxolitinib interferes with the downstream signaling events initiated by IL-7, influencing T cell homeostasis and other processes dependent on IL-7-mediated signaling. | ||||||
Baricitinib | 1187594-09-7 | sc-364730 sc-364730A | 5 mg 25 mg | $200.00 $664.00 | ||
Baricitinib is a JAK1 and JAK2 inhibitor that indirectly modulates IL-7 signaling. By targeting JAKs, Baricitinib disrupts the JAK-STAT pathway activated by IL-7, leading to alterations in T cell functions and other cellular responses regulated by IL-7. | ||||||
Resatorvid | 243984-11-4 | sc-476758 | 5 mg | $367.00 | ||
TAK-242 (Resatorvid) is a Toll-like receptor 4 (TLR4) inhibitor that indirectly influences IL-7 signaling. By inhibiting TLR4-mediated pathways, TAK-242 can modulate immune responses and affect the overall inflammatory milieu, potentially impacting IL-7-related processes in immune cells. This indirect modulation may alter the availability of IL-7 or its downstream effects on T cells and other IL-7-responsive cells. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
AG-490 is a Janus kinase (JAK) inhibitor that indirectly influences IL-7 signaling. By targeting JAKs, AG-490 disrupts the JAK-STAT pathway activated by IL-7, affecting downstream cellular responses. This indirect inhibition may alter IL-7-mediated effects on T cell development, survival, and other processes regulated by IL-7 signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a phosphoinositide 3-kinase (PI3K) inhibitor that can indirectly modulate IL-7 signaling. By inhibiting PI3K, Wortmannin disrupts downstream pathways involved in cell survival and growth, which are influenced by IL-7. This indirect modulation may affect IL-7-dependent processes, including the survival and proliferation of T cells and other IL-7-responsive cells. | ||||||
TG101348 | 936091-26-8 | sc-364740 sc-364740A | 5 mg 25 mg | $207.00 $515.00 | 6 | |
TG101348 is a JAK2 inhibitor that indirectly influences IL-7 signaling by targeting JAKs. Through the inhibition of JAK2, TG101348 disrupts the JAK-STAT pathway activated by IL-7, leading to alterations in T cell functions and other cellular responses regulated by IL-7. This indirect modulation may impact IL-7-mediated signaling and the subsequent effects on immune cell development and homeostasis. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinase (PI3K) inhibitor that can indirectly modulate IL-7 signaling. By inhibiting PI3K, LY294002 interferes with downstream pathways involved in cell survival and growth, which are influenced by IL-7. This indirect modulation may affect IL-7-dependent processes, including the survival and proliferation of T cells and other IL-7-responsive cells. | ||||||
BAY 61-3606 | sc-507485 | 2 mg | $345.00 | 1 | ||
BAY-61-3606 is a Syk (spleen tyrosine kinase) inhibitor that can indirectly modulate IL-7 signaling. By targeting Syk, BAY-61-3606 may influence downstream pathways involved in immune cell responses, potentially impacting IL-7-related processes in T cells and other IL-7-responsive cells. This indirect modulation may alter the availability of IL-7 or its downstream effects on immune cells. | ||||||